Isoniazid 300 MG

DRUG2 trials

Sponsors

Instituto Nacional de Salud Publica, Mexico, TASK Applied Science

Conditions

Diabetes MellitusLatent TuberculosisRifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)

Phase 2

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

CompletedNCT05473195

TASK Applied ScienceRifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)

Start: 2022-12-06End: 2024-04-16Updated: 2025-08-21

Phase 4

Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis

WithdrawnNCT03498534

Instituto Nacional de Salud Publica, MexicoDiabetes Mellitus, Latent Tuberculosis

Start: 2012-09-30End: 2013-12-31Updated: 2018-04-17

Related Papers

First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug

Journal of Antimicrobial Chemotherapy2024-04-245 citations